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ABSTRACT
Background In 30–50% of patients with colorectal
adenomatous polyposis, no germline mutation in the
known genes APC, causing familial adenomatous
polyposis, MUTYH, causing MUTYH-associated polyposis,
or POLE or POLD1, causing polymerase-proofreading-
associated polyposis can be identified, although a
hereditary aetiology is likely. This study aimed to explore
the impact of APC mutational mosaicism in unexplained
polyposis.
Methods To comprehensively screen for somatic low-
level APC mosaicism, high-coverage next-generation
sequencing of the APC gene was performed using DNA
from leucocytes and a total of 53 colorectal tumours
from 20 unrelated patients with unexplained sporadic
adenomatous polyposis. APC mosaicism was assumed if
the same loss-of-function APC mutation was present in
≥2 anatomically separated colorectal adenomas/
carcinomas per patient. All mutations were validated
using diverse methods.
Results In 25% (5/20) of patients, somatic mosaicism
of a pathogenic APC mutation was identified as
underlying cause of the disease. In 2/5 cases, the
mosaic level in leucocyte DNA was slightly below the
sensitivity threshold of Sanger sequencing; while in 3/5
cases, the allelic fraction was either very low (0.1–1%)
or no mutations were detectable. The majority of mosaic
mutations were located outside the somatic mutation
cluster region of the gene.
Conclusions The present data indicate a high
prevalence of pathogenic mosaic APC mutations below
the detection thresholds of routine diagnostics in
adenomatous polyposis, even if high-coverage
sequencing of leucocyte DNA alone is taken into
account. This has important implications for both routine
work-up and strategies to identify new causative genes
in this patient group.
INTRODUCTION
Adenomatous polyposis syndromes of the colorec-
tum are precancerous conditions characterised by
the presence of dozens to thousands of adenoma-
tous polyps, which, unless detected early and
resected, invariably result in colorectal cancer. The
phenotypic spectrum ranges from an early-onset
manifestation with high numbers of adenomas and
a positive family history to isolated late-onset
disease with low polyp burden.
To date, three inherited monogenic forms can be
delineated by molecular genetic analyses: (1)
autosomal-dominant familial adenomatous polyp-
osis (FAP), caused by heterozygous germline muta-
tions (http://www.lovd.nl/APC; http://www.umd.be/
APC; http://www.hgmd.cf.ac.uk) in the tumour
suppressor gene APC;1 (2) autosomal-recessive
MUTYH-associated polyposis, caused by biallelic
germline mutations (http://www.lovd.nl/MUTYH;
http://www.umd.be/MUTYH; http://www.hgmd.cf.
ac.uk) of the base excision repair gene MUTYH;2
and (3) autosomal-dominant polymerase-proofread-
ing-associated polyposis (PPAP), caused by specific
germline missense mutations in the polymerase
genes POLE and POLD1.3 Mutation detection
rates are strongly dependent on the colorectal
phenotype. In classical FAP, a pathogenic APC
germline mutation is identified in up to 90% of
index patients,4 5 whereas APC or MUTYH germ-
line mutations are detected in only 20–30% of
index cases with a mild disease course (attenuated
FAP).6–8 A PPAP has been reported in up to 7% of
families with unexplained multiple colorectal aden-
omas and carcinomas.9
In up to 50% of polyposis patients, no under-
lying germline mutation is identified, although a
hereditary basis is likely. A small fraction of cases
might be explained by deep intronic APC muta-
tions,10 rare missense mutations of the APC gene11
or mutations in other known cancer predisposition
genes.12–15 A recent genome-wide analysis of germ-
line copy number variants in 221 patients with
unexplained adenomatous polyposis identified a
group of genes that are likely to predispose to colo-
rectal adenoma formation.16
It is well known that the impact of low-level
mosaicism in hereditary (tumour) syndromes with a
high de novo mutation rate such as APC-related
FAP is underestimated.17–21 Several casuistic
reports of somatic and gonadal APC mosaicism
have been published,22–25 one patient was identi-
fied by next-generation sequencing (NGS).26
However, only two studies have addressed the issue
of mosaicism in a comprehensive manner.27 28
These studies detected low-level mutational APC
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mosaicism in 10–20% of leucocyte DNA among a selected
group of unrelated patients with suspected or confirmed APC de
novo mutation. Prescreening methods such as denaturing high-
performance liquid chromatography (DHPLC) or protein trun-
cation test (PTT) were shown to be more sensitive in terms of
uncovering mosaicism than Sanger sequencing. This suggests
that a number of mosaic cases are likely to be overlooked
during current routine diagnostics.22 27
To evaluate the impact of low-level APC mutational mosai-
cism below the detection threshold of Sanger sequencing (10–
15% mutated alleles) including mosaicism not visible in tissues
originating from the mesodermal germinal sheet such as leuco-
cytes at all, we have chosen a comprehensive approach that took
advantage of the more sensitive NGS method29 30 and have per-
formed systematic high-coverage sequencing of the APC gene in
DNA from leucocytes and multiple colorectal tumours (aden-
omas or carcinomas) in each of 20 unrelated patients with unex-
plained sporadic adenomatous polyposis.
MATERIALS AND METHODS
Patients/data collection
All patients in the present study had unexplained colorectal
adenomatous polyposis, that is, no germline mutation in the
APC or MUTYH genes was identified by Sanger sequencing of
the coding regions, deletion/duplication analysis using multiplex
ligation-dependent probe amplification (MPA), and screening
for pathogenic deep intronic APC mutations.10 31 32
Furthermore, neither of the two hotspot mutations in POLE
and POLD1 was present.9
The inclusion criteria for all patients enrolled in this study
were the presence of at least 20 synchronous or 40 metachro-
nous, histologically confirmed colorectal adenomas. All patients
were of central European origin according to family name and
self-reporting.
For high-throughput sequencing of leucocyte-derived and
adenoma-derived DNA, 20 unrelated patients with an incon-
spicuous family history were chosen for whom at least two colo-
rectal tumour samples (adenomas or carcinomas) were available,
which had to be separated anatomically by a distance of at least
10 cm. For screening of APC mosaicism in leucocyte-derived
NGS data, 80 additional unselected index patients with sporadic
disease were used (same inclusion criteria). The included
patients were recruited in the period from 1992 to 2011.
DNA extraction
Genomic DNA was extracted from peripheral EDTA-anticoagu-
lated blood samples using the standard salting-out procedure.
DNA of colorectal formalin-fixed and paraffin-embedded
(FFPE) tumour tissue was extracted from punches after careful
histological re-evaluation of representative sections, as described
elsewhere.33 Alternatively, 10-mm-thick sections were cut from
FFPE tissue blocks. After deparaffinisation, tumour tissue was
macrodissected from unstained slides. A previously marked
H&E-stained slide served as a reference. Extraction of FFPE
embedded tissue DNA was carried out using the BioRobot M48
Robotic Workstation and the corresponding MagAttract DNA
Mini M48 Kit (Qiagen, Hilden, Germany), in accordance with
the manufacturer’s protocol. The tissues were lysed overnight
with proteinase K, and the DNA was eluted in 150 mL Tris-HCl
(pH 7.6).
High-throughput sequencing and bioinformatics workflow
In 9 of the 20 polyp-screened patients, exome sequencing of
leucocyte and adenoma DNA was performed at the Max Planck
Institute for Molecular Genetics, Berlin, Germany. Library prep-
aration and whole-exome target enrichment was performed
according to Agilent’s SureSelect protocol (Human All Exon
50Mb v2, 2011) and as previously described.9 34 35
Multiplexed paired end sequencing was performed on the
Illumina HiSeq 2000 platform in accordance with the manufac-
ture’s protocol. Base calling and demultiplexing were performed
using Illumina’s CASAVA pipeline v1.7. Raw reads were mapped
to GRCh37/hg19 using BWA v0.5.836 and default parameters.
Enrichment statistics were calculated using Agilent’s SureSelect
target regions. Local realignment, quality value recalibration
and variant calling were performed using GATK v2.1–8.37
In-house tools and ANNOVAR38 were used to annotate and
filter the variants. Picard (http://broadinstitute.github.io/picard/)
was used to collect metrics. For leucocyte exome sequencing,
the mean on-target coverage of mapped reads was 71×, and
85% of bases were covered at ≥10× (see online supplementary
table S1). On average, 22 148 genetic variants per patient were
identified in the coding regions or the canonical splice sites.
In the remaining 11 patients, sequencing of colorectal tumour
DNA samples was performed at first using the TruSight Cancer
Panel (Illumina).
Whole-exome sequencing of the leucocyte screening cohort
(n=80) was performed at the Yale Center for Genome Analysis,
New Haven, USA, via capture using NimbleGen 2.1M human
exome array followed by paired-end sequencing on a HiSeq
2000 instrument, as previously described.9 34 Targeted bases
were covered by a mean of 67 independent reads, with an
average of 94% of all bases covered eight or more times (see
online supplementary table S1). Reads were aligned to the hg19
human reference genome using ELAND (Illumina).
Single-nucleotide variants along with short insertions and dele-
tions were identified using SAMtools software.
For validation of suspected APC mosaic mutations, targeted
sequencing using the FAP MASTR Kit (Multiplicom) with high
coverage (read depths >1000) for leucocyte DNA was per-
formed on a MiSeq platform (Illumina). In addition, the identi-
fied variants were validated by Sanger sequencing of the
corresponding region using standard protocols (primer
sequences available upon request).
NGS data were filtered for truncating APC variants (nonsense
mutations, frameshift deletions/insertions and mutations at
highly conserved splice sites) present in at least 5% of reads
using Cartagenia Bench Lab NGS v4.0 (Leuven, Belgium) or the
SeqPilot software ( JSI Medical Systems). Detailed visual inspec-
tion of variants was done in a read browser (Integrative
Genomics Viewer).
RESULTS
The majority of the patients presented with an attenuated colo-
rectal phenotype (late-onset disease and/or <100 colorectal
adenomas). The mean age at diagnosis was 45 years (range 14–
73 years). None of the patients had a conspicuous family history
(sporadic or isolated cases). The family history was classified as
inconspicuous if there was no evidence of polyposis or any
other early-onset FAP-related tumour in the first-degree or
second-degree relatives of the proband. The basic clinical fea-
tures are summarised in online supplementary table S2.
To screen for APC mosaicism, a systematic search was con-
ducted for the presence of loss-of-function APC mutations in
multiple colorectal tumours from individual patients. For this
approach, 53 colorectal tumours (51 adenomas, 2 carcinomas)
from 20 unrelated patients were analysed. Mutational APC
mosaicism was assumed if the same pathogenic loss-of-function
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mutation was present and validated in more than one tumour
(workflow shown in figure 1).
In 5 of the 20 polyp-screened patients, APC mosaicism could
be detected (table 1). In patient F5018, the same nonsense APC
mutation (c.1660C>T;p.Arg554*) was recognised in leucocyte
DNA (11% of the reads=allelic fraction; read depth 286×) and
two adenomas (allelic fraction 25% (4/16) and 60% (3/5),
respectively) (figure 2A and table 1). To confirm the degree of
mosaicism in leucocyte-derived DNA, targeted high-throughput
sequencing of the APC gene with high coverage was performed
using a commercial assay (Multiplicom). Again, a level of
around 10% mutated reads was found (figure 2B). Sanger
sequencing revealed only a very discrete peak (figure 2C). In
one of the adenomas, a further APC nonsense mutation
(c.4348C>T;p.Arg1450*) was detected in 33% (4/12) of reads,
which indicate a possible somatic mutation of the wildtype
allele (“second hit”) (see online supplementary figure S1).
In patient F1243, the same nonsense APC mutation
(c.3283C>T;p.Gln1095*) was found in both adenomas and an
allelic fraction of 1% in leucocyte DNA (table 1 and online sup-
plementary figure S2). In patient F1676, an identical frameshift
APC mutation (c.2840_2841delGT;p.Cys947Phefs*15) was
identified in both adenomas and with an allelic fraction of 9%
in leucocyte DNA. Sanger sequencing revealed only very dis-
crete peaks representing the frameshift (table 1 and online sup-
plementary figure S3). In one of the adenomas, a potential
second hit (c.4348C>T;p.Arg1450*) was detected in 18% (6/
34) of reads. In patient F5000, an identical frameshift APC
mutation (c.4127_4128delAT;p.Tyr1376Cysfs*9) was found in
all four polyps but not in leucocyte DNA (table 1 and figure 3).
In all patients, the suspected mosaic mutations could be revealed
in additional polyp samples by Sanger sequencing (figure 2D
and online supplementary table S3, figure S2C and 3D). Using
targeted high-throughput sequencing of the APC gene (see
above), the levels of mutated reads were confirmed in leucocyte-
derived DNA with high coverage in patients F1243 and F1676
(table 1 and online supplementary figure S2B and 3C). In
patient F5000, the APC mutation, found in seven adenomas,
was not detectable in leucocyte-derived DNA in spite of a cover-
age of 2650×.
Furthermore, a nonsense APC mutation (c.1495C>T;p.
Arg499*), detected in one adenoma by targeted NGS, could be
confirmed in two of three additional polyps by Sanger sequen-
cing (patient F1543, table 1 and online supplementary
figure S4). In leucocyte DNA, the mutation was only detectable
at a very low-level with high-coverage NGS (allelic fraction
0.1%, 22/17 460 reads, table 1).
To explore the sensitivity of high-coverage leucocyte-derived
NGS alone to uncover low-level APC mosaicism, we performed
a systematic screen of exome sequencing data in 80 additional
patients (figure 1). In 12 patients, APC mosaicism was suspected
due to the detection of a truncating APC mutation in at least
5% of reads. From 10 of those patients, we were able to receive
at least two colorectal tumours for validation by Sanger sequen-
cing (29 adenomas, 1 carcinoma). In two of these 10 patients,
the mutation (detected in 8–9% of reads in leucocyte DNA)
could be confirmed in 2/3 and 4/4 polyps, respectively (F1252
and F1727, table 1, online supplementary figures S5 and 6). On
leucocyte level, the mutations could be confirmed by targeted
sequencing with high coverage.
The positions of all seven mosaic mutations in relation to the
described somatic mutations and the mutation cluster region
(MCR) of the APC gene are shown in online supplementary
figure S7.
All patients with APC mosaicism had an attenuated polyposis
phenotype; clinical details are provided in table 2. At the time
of the last contact (telephone interview), only one child had a
colonoscopy with normal findings at 38 years of age (the age of
all 12 children of the mosaic index cases ranges between 6 and
40 years, median 26 years), no symptoms such as gastrointes-
tinal bleedings were reported.
DISCUSSION
In a number of patients with colorectal adenomatous polyposis,
no germline mutation in the known causal genes can be identi-
fied. Based on previous data from our group and others, it can
be hypothesised that a substantial fraction of mosaic cases are
overlooked in routine diagnostics using Sanger sequencing of
leucocyte DNA.22 27 To elucidate the frequency of undiscovered
APC mosaicism in sporadic polyposis patients, we systematically
screened multiple adenomas from a number of patients with
unexplained polyposis using NGS.
Figure 1 Workflow illustrating the overall procedure of screening for
somatic APC mutational mosaicism.
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In the previous studies performed by our group27 and Hes
et al,28 APC mutational mosaicism was detected in 11% and
20% in a selected group of unrelated patients with suspected or
confirmed de novo APC mutation, respectively. In both studies,
a combination of sensitive methods, that is, PTT, DHPLC,
denaturing gradient gel electrophoresis (DGGE) and Sanger
sequencing was applied.
However, related to the number of APC and MUTYH
mutation-negative index patients included in these study cohorts
(450 in our previous study and 295 in the study of Hes et al),
the prevalence of uncovered mosaicism is much less. In our
current, well-characterised overall cohort of 261 unrelated
patients with unexplained adenomatous polyposis,
approximately 80% of patients presented with apparent spor-
adic disease. When applying this percentage to the mutation
negative cohorts of the above-mentioned studies, the frequency
of somatic APC mosaicism in sporadic unexplained adenoma-
tous polyposis can be estimated to be around 2–4%. These
numbers are comparable with our present finding in 80 unse-
lected, sporadic polyposis patients: based on a systematic screen-
ing in NGS data of leucocyte-derived DNA and subsequent
sequencing of the respective APC exons in adenoma DNA, low-
level APC mosaicism was detected in two cases (2.5%).
In contrast, the multiple adenoma approach identified somatic
mosaicism for a pathogenic APC mutation in 25% (5/20) of
patients with sporadic disease in whom no APC and MUTYH









of polyps Truncating APC mutation
Sequencing method (number of
mutant reads/read depth=% mutant
reads)
(A) Mosaic cases in polyp screening cohort (n=20)
F1243 L gc.3283C>T; p.Gln1095* Exome (2/213=1%);Multiplicom (33/1875=1.8%)T1 Tubulovillous adenoma Low grade Approximately 50 cmab ano Exome (4/35=11%)T2 Tubulovillous adenoma,
partly hyperplastic polyp
Low grade Approximately 40 cm
ab ano
Exome (11/39=28%)
F1543 L gc.1495C>T;p.Arg499* Multiplicom (22/17 460=0.1%)T1 Tubular adenoma Low grade Rectum SangerT2 Tubular adenoma Low grade Caecum Sanger
T3 Tubular adenoma Low grade Rectum TruSight (65/364=18%)
F1676 L g c.2840_2841delGT;p.Cys947Phefs*15 Exome (19/220=9%); Multiplicom (129/2149=6%)T1 Tubular adenoma Low grade Transverse colon Exome (16/55=29%)




F5000 L mutation not detectable Exome (0/67=0%);
Multiplicom (0/2650=0%)
T1 Tubular adenoma Low grade Descending colon g c.4127_4128delAT;p.Tyr1376Cysfs*9 Exome (2/3=67%)T2 Tubular adenoma Low grade 13 cm distal fromvalvula bauhini Exome (23/25=92%)T3 Tubular adenoma Low grade 33 cm distal fromvalvula bauhini Exome (12/28=43%)
T4 Tubular adenoma Low grade 33 cm distal from
valvula bauhini
Exome (2/12=17%)
F5018 L gc.1660C>T;p.Arg554* Exome (32/286=11%);Multiplicom (97/1061=9%)T1 Tubular adenoma Low grade Sigmoid colon Exome (4/16=25%)




(B) Mosaic cases in leucocyte screening cohort (n=80)
F1252 L g c.896_897delCT;p.Ser299Leufs*27 Exome (7/77=9%);Multiplicom (344/3643=9%)T1 Tubulovillous adenoma Low grade Sigmoid colon Sanger
T2 Tubular adenoma Low grade Approximately 40 cm
ab ano
Sanger
F1727 L g c.2240C>G;p.Ser747* Exome (2/26=8%);Multiplicom (113/2083=5%)T1 Tubulovillous adenoma Low grade Approximately 23 cmab ano SangerT2 Tubulovillous adenoma Low grade Approximately 45 cmab ano SangerT3 Tubulovillous adenoma Low grade Approximately 39 cmab ano Sanger
T4 Tubulovillous adenoma Low grade Approximately 32 cm
ab ano
Sanger
L, leucocyte DNA; T, adenoma DNA.
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mutations had been identified in routine diagnostics. According
to this result, pathogenic somatic APC mosaicism is considerably
higher than previous data might have been suggested.
All mosaic mutations were validated by two different
methods excluding allele drop-out and technical artefacts. Each
tumour-derived DNA sample originated from a single
Figure 2 APC mutation c.1660C>T;p.Arg554* in mosaic state (patient F5018): (A) Exome sequencing data of leucocyte DNA (11%; 32 mutant
reads, coverage 286×) and of adenoma DNA (T1: 25%; 4 mutant reads, coverage 16×, and T2: 60%; 3 mutant reads, coverage 5×) (Integrative
Genomics Viewer) (B) Targeted next-generation sequencing data of leucocyte DNA (9%; 97 mutant reads, coverage 1061×); FAP MASTR Kit
(Multiplicom). The mutation is shown in the ‘peak view’ of the analysis software SeqPilot ( JSI Medical Systems), where the height of the peaks
corresponds to the number of reads. (C) Sanger sequencing of the corresponding region (leucocyte DNA). (D) Sanger sequencing of the
corresponding region (additional adenoma sample, reverse sequence).
Figure 3 APC mutation c.4127_4128delAT;p.Tyr1376Cysfs*9 in mosaic state (patient F5000): (A) Exome sequencing data of adenoma DNA (T1:
67%; 2 mutant reads, coverage 3×, T2: 92%; 23 mutant reads, coverage 25×, T3: 43%; 12 mutant reads, coverage 28× and T4: 17%; 2 mutant
reads, coverage 12×) (Integrative Genomics Viewer). (B) Sanger sequencing of the corresponding region (adenoma DNA of T4, reverse sequence).
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independent adenoma. At least two adenomas with the same
APC mutation were separated anatomically by a distance of
>10 cm, the majority even grew in different colonic segments
(table 1). None of the mosaic patients reported a conspicuous
family history regarding siblings, parents or second-degree
ancestors, which is consistent with the assumption of a de novo
event.
Interestingly, six of the seven mosaic mutations (five from
polyp-screened and two from leucocyte-screened patients) were
located outside the somatic MCR (codons 1286–1513) of the
APC gene.39 In contrast, the two presumed second hits, both of
which were identified in a single adenoma (F1676 and F5018),
affect the same codon (c.4348C>T;p.Arg1450*), which repre-
sents a mutational hotspot within the MCR (see online supple-
mentary figure S7).
In 2/5 cases, the mutation level in leucocyte-derived DNAwas
slightly below the detection threshold of Sanger sequencing
(10–15% mutated alleles), which explains why the mutation
was not found during routine diagnostics. Apart from NGS,
these cases might have been identified with other sensitive
methods such as PTT, DHPLC, DGGE, high-resolution melting
or pyrosequencing.27 28 40 However, the use of these techniques
is decreasing in clinical practice and even in those cases, add-
itional non-mesoderm tissue is usually required to confirm
mosaicism.
In 3/5 cases, the mutation level (allelic fraction) in leucocyte-
derived DNA was very low (0.1–1%) or the mutation was not
detectable at all despite deep sequencing. It can be presumed
that in cases like patient F5000 an early postzygotic mutation
must have occurred after mesoderm and endoderm specifica-
tion.17 In all three patients, the mutation was present in at
least three colorectal adenomas, a finding that is strongly sug-
gestive of mosaicism. These mosaic mutations are undetectable
even in high-coverage NGS data from leucocyte-derived DNA
alone since screening for mosaic mutations below a level of
5% mutated reads reveals too much false positive results and is
thus not feasible in clinical practice. This is also demonstrated
in our screening cohort of 80 patients, where 8/10 potential
low-level mosaic mutations could not be confirmed by examin-
ation of tumour-derived DNA. As a consequence, such muta-
tions, which represent a magnitude of around 60% of mosaic
cases in our cohort of 20 patients, can only be uncovered by
screening of additional tissues and usually adenomas are easiest
to get and the most promising tissue to identify mosaic
mutations.
Hence, our data confirm theoretical considerations of a high
frequency of somatic mosaicism not detectable in leucocyte
DNA. Although a small number of such cases have been
reported in recent years by Hes et al,28 40 to date, no systematic
investigation of the clinical relevance of APC mosaicism has
been conducted. Given the number of cases in this study, the
results are likely to be representative. The inclusion of multiple
adenomas into the routine workup is a promising way to iden-
tify those cases and to increase the diagnostic sensitivity
considerably.
While somatic mosaicism can contribute to deviations from
the predicted phenotype, the level of mosaicism in leucocytes
shows no consistent correlation with disease severity. In the
present seven patients with somatic mosaicism, the polyps were
not restricted to a particular colonic segment; in fact, in two
cases even the upper gastrointestinal tract was affected.
Nonetheless, all of our mosaic cases presented with an attenu-
ated colorectal disease according to age at onset and/or polyp
burden, despite the fact that the position of the mutation in the
APC gene would have been expected to result in classical
(typical) FAP. As a consequence, the offspring of mosaic patients
may develop a more severe phenotype than the affected parent.
This is relevant for genetic counselling and the decision as to
when surveillance should commence.
The diagnosis of mosaicism is also important in terms of esti-
mating the recurrence risk in relatives. While siblings and
parents will not be affected, the risk for children is up to 50%,
depending on the distribution of the mutation in different
tissues. Patients in whom mosaicism is restricted to the endo-
derm are thought to have a low risk of transmitting the muta-
tion since the primordial germ cells should not be affected.17
A yet unknown polyposis in children of our index cases
cannot be excluded for sure, although there is no evidence for
this so far.
To the best of our knowledge, this is the first study that sys-
tematically evaluates the impact of APC mosaicism using mul-
tiple tumour samples in a sufficient number of patients with
unexplained polyposis. In conclusion, this work suggests that
low-level APC mosaic mutations below the threshold of routine
diagnostics contribute significantly to the aetiology of adenoma-
tous polyposis. While the frequency of detectable somatic APC


















(A) Patients of polyp screening cohort









F1543 60 21–50 Whole colon No No Normal Unremarkable
F1676 55 51–100 Whole colon No No Normal Gastric fundic gland
polyps, gastric foveolar
adenoma










(B) Patients of leucocyte screening cohort
F1252 40 51–100 Distal pronounced No No Normal Unremarkable
F1727 30 51–100 Whole colon No No Normal Unremarkable
Spier I, et al. J Med Genet 2016;53:172–179. doi:10.1136/jmedgenet-2015-103468 177
Cancer genetics
 on 16 A








enet: first published as 10.1136/jm






mosaicism in leucocyte-derived DNA alone may not exceed 3–
4%, even when more sensitive methods are applied, a multiple
adenoma approach can increase the diagnostic yield to 20–30%.
Our findings may have important implications for both routine
diagnostics and research strategies. The inclusion of APC muta-
tion screening in multiple (≥2) colorectal adenomas can clarify
the diagnosis in up to one-quarter of mutation-negative patients,
and thus should be considered in all cases with proven (>20
adenomas) and sporadic disease (inconspicuous family history)
in whom no pathogenic APC, MUTYH, POLE or POLD1 muta-
tion is detected. It also might be reasonable to carefully exclude
APC mutational mosaicism prior to admittance of this patient
group in studies that aim to identify new causative highly pene-
trant genes.
DATABASES/URLS
APC locus-specific mutation databases: http://www.lovd.nl/
APC; http://www.umd.be/APC; http://www.hgmd.cf.ac.uk
IGV (Integrative Genomics Viewer): http://www.broad
institute.org/igv/
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